BS Summary: This article contains 11 faulty reasoning types, including Negativity Bias, Optimism Bias, and Anecdotal, with Attempt to Sell a Product or Service as the most egregious example at 24.1% saturation with 76 hits. Analysis detected 280 faulty-reasoning hits from 315 analyzed words, generating a BS Score of 30% and a BS Rank of 14% (19,022 of 21,886 articles). This article is better (less manipulative) than 86.90% of the article peer group.
Newsletter The Readout
Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
SEBASTIEN BOZON/AFP via Getty Images
By Meghana Keshavan and John Wilkerson
Meghana Keshavan covers biotech and contributes to The Readout newsletter .
John writes about the politics of health care, and he is the author of the twice-weekly D.C.
Diagnosis newsletter .
You can reach John on Signal at John_Wilkerson.07.
Want to stay on top of the science and politics driving biotech today?
Sign up to get our biotech newsletter in your inbox.
ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic.
Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to promote Medicare’s new obesity drug discount program.
I got coffee with my cousin this morning here in SF.
Before leaving for his job at an AI behemoth, he said the bone-chilling July gloom is perfect “working weather.”
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology , drug development , Drug prices , research
Submit a correction request Reprints
Biotech Correspondent
Washington Correspondent
STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
6speakers51%attributed speech154writer words
Voice mapSelect a segment to jump to its words
Selected voice
72%flagged-word coverageSTAT+
47 attributed words29% of attributed speech74% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.